1. Home
  2. ARCC vs BMRN Comparison

ARCC vs BMRN Comparison

Compare ARCC & BMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ares Capital Corporation

ARCC

Ares Capital Corporation

HOLD

Current Price

$18.82

Market Cap

13.6B

Sector

Finance

ML Signal

HOLD

Logo BioMarin Pharmaceutical Inc.

BMRN

BioMarin Pharmaceutical Inc.

HOLD

Current Price

$59.30

Market Cap

11.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARCC
BMRN
Founded
2004
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
13.6B
11.4B
IPO Year
2004
1999

Fundamental Metrics

Financial Performance
Metric
ARCC
BMRN
Price
$18.82
$59.30
Analyst Decision
Buy
Buy
Analyst Count
11
18
Target Price
$21.36
$88.22
AVG Volume (30 Days)
5.4M
1.7M
Earning Date
04-28-2026
05-04-2026
Dividend Yield
10.28%
N/A
EPS Growth
N/A
N/A
EPS
0.13
0.54
Revenue
N/A
$1,313,646,000.00
Revenue This Year
$5.77
$15.02
Revenue Next Year
$2.29
$12.23
P/E Ratio
$141.69
$111.13
Revenue Growth
N/A
17.62
52 Week Low
$17.40
$49.26
52 Week High
$23.42
$66.28

Technical Indicators

Market Signals
Indicator
ARCC
BMRN
Relative Strength Index (RSI) 57.42 59.30
Support Level $18.78 $54.24
Resistance Level $19.36 $59.77
Average True Range (ATR) 0.31 1.63
MACD 0.05 0.18
Stochastic Oscillator 95.71 75.39

Price Performance

Historical Comparison
ARCC
BMRN

About ARCC Ares Capital Corporation

Ares Capital Corp is a United States-based closed-ended specialty finance company. Its investment objective is to generate both current income and capital appreciation through debt and equity investments. The company focuses on investing in first lien senior secured loans (including unitranche loans, which are loans that combine both senior and subordinated debt, generally in a first lien position) and second lien senior secured loans. In addition to senior secured loans, the company also invests in subordinated loans and preferred equity, it also makes common equity investments.

About BMRN BioMarin Pharmaceutical Inc.

BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.

Share on Social Networks: